Inclusion Criteria:  Signed and dated informed consent by the patient or the patient's Legally Acceptable Representative (LAR) Age ≥18 years old at time of diagnosis of R/R-DLBCL Histologically confirmed diagnosis of DLBCL according to World Health Organization (WHO) classification, including histologically confirmed diagnosis of high-grade lymphoma with double and triple hit: DLBCL with MYC and BCL2/BCL6 translocation (double-hit) and MYC and BCL2 and BCL6 translocations (triple-hit) Availability of data on first-line (and second-line, if applicable) DLBCL therapy (with the minimum data required including treatment type, number of cycles and response) Relapsed or refractory DLBCL after at least one prior systemic therapy, and prior to second- or third-line therapy for DLBCL (previous treatment can include ASCT) Not planning to receive HD-ASCT at enrolment  Exclusion Criteria:  Concurrent participation in an interventional clinical study Receiving ASCT therapy (note: having received ASCT in the past is not an exclusion criterion)